Brief: Shanghai Bio-Heart Biological Technology Receives Approval From China Securities Regulatory Commission
Oct 17 (Reuters) - Shanghai Bio-heart Biological
Technology Co Ltd 2185.HK :
* RECEIVED OFFICIAL APPROVAL FROM CHINA SECURITIES
REGULATORY
COMMISSION
* APPROVAL FOR IMPLEMENTATION OF H SHARE FULL CIRCULATION
PROGRAMME OF CO
* APPROVAL FOR UP TO 100.1 MILLION DOMESTIC SHARES AND 74.5
MILLION UNLISTED FOREIGN SHARES CONVERTED TO H SHARES
Further company coverage: 2185.HK
Recent news on Shanghai Bio-heart Biological Technology
See all newsBrief: Shanghai Bio-Heart Biological Technology Says NMPA Approves Bioheart Bioabsorbable Drug-Eluting Stents
Brief: Shanghai Bio-Heart Biological Technology Says Iberis Rdn System Completes Registration In Vietnam
Brief: Shanghai Bio-Heart Biological Technology Says Iberis RDN System Completed Registration In Thailand
Brief: Shanghai Bio-Heart Biological Technology Says Iberis RDN System Completes Registration With MHRA In UK
Brief: Shanghai Bio-Heart Biological Technology's Controlling Shareholder Increases Shareholding